A preliminary study of the role of extracellular -5′- nucleotidase in breast cancer stem cells and epithelial-mesenchymal transition

In Vitro Cellular and Developmental Biology - Animal

Volumn 53, Issue 2, 2017, Pages 132-140

  Yu, Jiangang ^a   Liao, Xiaohong ^a   Li, Luying ^a   Lv, Lei ^a   Zhi, Xiuling ^a   Yu, Jerry ^a,b   Zhou, Ping ^a  

^a FUDAN UNIVERSITY   (China)

^b University of Louisville School of Medicine   (United States)

Author keywords

Breast cancer; CD73; Epithelial mesenchymal transition; Tumor stem cell

Indexed keywords

5' NUCLEOTIDASE; RECOMBINANT PROTEIN;

BREAST TUMOR; CANCER STEM CELL; ENZYMOLOGY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR SPACE; FEMALE; HUMAN; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; TUMOR CELL LINE;

5'-NUCLEOTIDASE; BREAST NEOPLASMS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR SPACE; FEMALE; HUMANS; NEOPLASTIC STEM CELLS; RECOMBINANT PROTEINS; SPHEROIDS, CELLULAR;

EID: 84991336327     PISSN: 10712690     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11626-016-0089-y     Document Type: Article

References (50)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983–3988
2. Aliagas E, Vidal A, Texidó L, Ponce J, Condom E, et al. (2014) High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors. Mediat Inflamm 2014:509027
3. Allard B, Pommey S, Smyth MJ, Stagg J (2013) Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res 19:5626–5635
4. Allard B, Turcotte M, Spring K, Pommey S, Royal I, et al. (2014) Anti-CD73 therapy impairs tumor angiogenesis. Int J Cancer 134:1466–1473
5. Beavis PA, Divisekera U, Paget C, Chow MT, John LB, et al. (2013) Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A 110:14711–14716
6. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730–737
7. Calloni R, Cordero EA, Henriques JA, Bonatto D (2013) Reviewing and updating the major molecular markers for stem cells. Stem Cells Dev 22:1455–1476
8. Cojoc M, Mäbert K, Muders MH, Dubrovska A (2014) A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Semin Cancer Biol 31:16–27
9. Creighton CJ, Chang JC, Rosen JM (2010) Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia 15:253–260
10. Deaglio S, Robson SC (2011) Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv Pharmacol 61:301–332
11. Derynck R, Muthusamy BP, Saeteurn KY (2014) Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition. Curr Opin Cell Biol 31C:56–66
12. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, et al. (2014) Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64:252–271
13. Duan JJ, Qiu W, Xu SL, Wang B, Ye XZ, et al. (2013) Strategies for isolating and enriching cancer stem cells: well begun is half done. Stem Cells Dev 22:2221–2239
14. Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, et al. (2014) Breast cancer in China. Lancet Oncol 15:e279–e289
15. Fantozzi A, Gruber DC, Pisarsky L, Heck C, Kunita A, et al. (2014) VEGF-mediated angiogenesis links EMT-induced cancer stemness to tumor initiation. Cancer Res 74:1566–1575
16. Fillmore CM, Kuperwasser C (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10:R25
17. Friedmann-Morvinski D, Verma IM (2014) Dedifferentiation and reprogramming: origins of cancer stem cells. EMBO Rep 15:244–253
18. Gudadze M, Kankava Q, Mariamidze A, Burkadze G (2014) Features of CD44+/CD24-low phenotypic cell distribution in relation to predictive markers and molecular subtypes of invasive ductal carcinoma of the breast. Georgian Med News 228:81–87
19. Häusler SF, Del Barrio IM, Diessner J, Stein RG, Strohschein J, et al. (2014) Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion. Am J Transl Res 6:129–139
20. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, et al. (2010) Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 148:3–15
21. Horenstein AL, Chillemi A, Zaccarello G, Bruzzone S, Quarona V, et al. (2013) A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. Oncoimmunology 2:e26246
22. Kothari AN, Mi Z, Zapf M, Kuo PC (2014) Novel clinical therapeutics targeting the epithelial to mesenchymal transition. Clin Transl Med 3:35
23. Kreso A, Dick JE (2014) Evolution of the cancer stem cell model. Cell Stem Cell 14:275–291
24. Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15:178–196
25. Liu Y, Nenutil R, Appleyard MV, Murray K, Boylan M, et al. (2014) Lack of correlation of stem cell markers in breast cancer stem cells. Br J Cancer 110:2063–2071
26. Loi S, Pommey S, Haibe-Kains B, Beavis PA, Darcy PK, et al. (2013) CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A 110:11091–11096
27. Mallini P, Lennard T, Kirby J, Meeson A (2014) Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev 40:341–348
28. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715
29. Marcato P, Dean CA, Giacomantonio CA, Lee PW (2011a) Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle 10:1378–1384
30. Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, et al. (2011b) Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 29:32–45
31. Nakaya Y, Sheng G (2013) EMT in developmental morphogenesis. Cancer Lett 341:9–15
32. O’Connor ML, Xiang D, Shigdar S, Macdonald J, Li Y, et al. (2014) Cancer stem cells: a contentious hypothesis now moving forward. Cancer Lett 344:180–187
33. Phillips TM, McBride WH, Pajonk F (2006) The response of CD24(−/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98:1777–1785
34. Puisieux A, Brabletz T, Caramel J (2014) Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 16:488–494
35. Reiman JM, Knutson KL, Radisky DC (2010) Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells. Cancer Res 70:3005–3008
36. Serra S, Horenstein AL, Vaisitti T, Brusa D, Rossi D, et al. (2011) CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood 118:6141–6152
37. Steinestel K, Eder S, Schrader AJ, Steinestel J (2014) Clinical significance of epithelial-mesenchymal transition. Clin Transl Med 3:17
38. Terp MG, Olesen KA, Arnspang EC, Lund RR, Lagerholm BC, et al. (2013) Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells. J Immunol 191:4165–4173
39. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, et al. (2013) Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J 27:13–24
40. Vicente-Dueñas C, Hauer J, Ruiz-Roca L, Ingenhag D, Rodríguez-Meira A et al (2014) Tumoral stem cell reprogramming as a driver of cancer: Theory, biological models, implications in cancer therapy. Semin Cancer Biol 32:3–9
41. Vidal SJ, Rodriguez-Bravo V, Galsky M, Cordon-Cardo C, Domingo-Domenech J (2014) Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene 33:4451–4463
42. Wang L, Tang S, Wang Y, Xu S, Yu J, et al. (2013) Ecto-5′-nucleotidase (CD73) promotes tumor angiogenesis. Clin Exp Metastasis 30:671–680
43. Wang L, Zhou X, Zhou T, Ma D, Chen S, et al. (2008) Ecto-5′-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol 134:365–372
44. Yang Q, Du J, Zu L (2013) Overexpression of CD73 in prostate cancer is associated with lymph node metastasis. Pathol Oncol Res 19:811–814
45. Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14:818–829
46. Zhi X, Chen S, Zhou P, Shao Z, Wang L, et al. (2007) RNA interference of ecto-5′-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion. Clin Exp Metastasis 24:439–448
47. Zhi X, Wang Y, Yu J, Zhang L, Yin L, et al. (2012) Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer. IUBMB Life 64:911–920
48. Zhi X, Wang Y, Zhou X, Yu J, Jian R, et al. (2010) RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells. Cancer Sci 101:2561–2569
49. Zhou P, Zhi X, Zhou T, Chen S, Li X, et al. (2007a) Overexpression of ecto-5′-nucleotidase (CD73) promotes T-47D human breast cancer cells invasion and adhesion to extracellular matrix. Cancer Biol Ther 6:426–431
50. Zhou X, Zhi X, Zhou P, Chen S, Zhao F, et al. (2007b) Effects of ecto-5′-nucleotidase on human breast cancer cell growth in vitro and in vivo. Oncol Rep 17:1341–1346